AMG20160283

AMG20160283

A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 592 in Adult Subjects With Steroid Refractory Chronic Graft Versus Host Disease (cGVHD) 


Treatment


Inclusion criteria


Exclusion criteria


Participating sites

Link